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Abstract
Background and purpose Vascular risk factors are suboptimally managed internationally. This study investigated time trends in risk factors diagnosed prior-to-stroke and their treatment, and factors associated with appropriate medication use.
Methods 4416 patients with a first stroke were registered in the populationbased South London Stroke Register from 1995-2011. Previously diagnosed risk factors and usual medications were collected from patients' primary care and hospital records. Trends and associations were assessed using multivariate logistic regression.
Results 72% of patients were diagnosed previously with one or more risk factor; 30% had diagnosed risk factors which were untreated. Hypercholesterolemia increased significantly over the study period; MI and TIA prevalences decreased.
Antiplatelet prescription increased in AF, MI, and TIA (AF: 37%-51%, P<0.001; MI: 48%-69%, P<0.001; TIA: 49%-61%, P=0.015). Anticoagulant prescription for AF showed a non-significant increase (12%-23%; P=0.059). Fewer older patients with AF were prescribed anticoagulants (age > 85 v < 65: aRR 0.19, 95% CI 0.08-0.41). Black ethnicity (aRR 1.17, 95% CI 1.10-1.23) and female sex (aRR 1.09, 95% CI 1.03-1.15) were associated with increased antihypertensive drug prescription; other medications did not vary by ethnicity or sex.
Conclusions Antiplatelet and cholesterol-lowering treatment prescribing have improved significantly over time; however, only a minority with AF received anticoagulants, and this did not improve significantly. Overall, 30% of strokes occurred in patients with previously diagnosed but untreated risk factors.
Background
Stroke remains a major preventable cause of morbidity and mortality internationally. [1] In addition to lifestyle modification, cost-effective drug treatments for hypertension, hypercholesterolemia, and atrial fibrillation (AF) reduce stroke risk, heart disease and mortality. [2] [3] [4] Despite international guidance aimed at improving primary prevention, risk factor control rates remain low. [5] [6] [7] Suboptimal control is associated with inadequate risk factor detection and treatment, ethnic differences in risk factor susceptibility and response to treatment, socio-economic deprivation, and poor treatment adherence. [5, [7] [8] [9] Several studies have found ethnic differences in stroke risk factors. A US casecontrol study found that hypertension and diabetes were significantly more prevalent among black than white stroke patients, whereas AF was significantly more prevalent in white patients. [10] Similar results were reported by the South London Stroke Register (SLSR) from 1995-98. [11] A US cross-sectional study found that apparent ethnic differences in stroke risk factors were explained by differences in income. [12] We sought to examine trends from 1995-2011 in prior-to-stroke risk factors and use of appropriate treatment, using data from the SLSR. We aimed to investigate variation in risk factors by age, sex, ethnicity, socio-economic group, and stroke subtype, and factors associated with appropriate treatment.
Methods
The methods of the SLSR have been described previously, [13] and are summarised below. The SLSR is a population-based register recording all first strokes in a defined region of Lambeth and Southwark, with a population of 310,028 according to the 2001 UK Census, with 63% white, 28% black (9% black Caribbean, 15% black African, and 4% black other), and 9% other ethnic group.
By 2011, the source population had increased to 357,308, with 56% white, 25% black (7% black Caribbean, 14% black African, 4% black other) and 18% other.
The largest increase was in those aged 49-59 (49%); the proportion aged 65+ fell by 10%.
Overlapping notification sources were used to increase data completeness. Data were collected by study nurses and field workers. Data were analysed in four-year groups to increase numbers per group.
Demographic trends were assessed using the Chi-squared test for trends. Risk factor and medication trends were assessed in logistic regression models adjusting for age, sex, ethnicity, stroke subtype, and deprivation with the year of stroke as an explanatory variable. Associations with risk factors and prescribed medication were assessed in logistic regression models incorporating sex, age, ethnicity, stroke subtype, deprivation, and year of stroke. P values <0.05 were regarded as statistically significant. Risk ratios were estimated using Zhang and Yu's method. [15] Inter-variable interactions were assessed for each analysis.
Analyses omitted patients with missing data. Analyses were conducted using R. [16] 
Results
Between January 1995 and 2011, 4416 patients were registered (table 1). Patient median age was 72.4 years (interquartile range 61.2-81.1); ethnicities were white (70.5%), black (21.3%; 13.0% black Caribbean, 7.6% black African, and 0.6% black other), and other (5.7%). Stroke subtypes were ischemic (73.8%), ICH (12.7%), SAH (5%), and undefined (8.4%). White and black patients had significantly lower Carstairs scores than other ethnicities, but the difference was small (mean score [higher=more deprived]: white 9.421, black 9.662, other 10.21;
P=0.006). Data completeness was high for all variables (ethnicity 97%, stroke subtype 96%, risk factors 95-97%; prescribed medication 96-97%). There were no significant inter-variable interactions in any analysis.
Risk factor trends
Risk factor trends are reported in figure 1 and table 1. 72% of patients had one or more risk factors diagnosed prior-to-stroke. Overall risk factor prevalences were: hypertension, 64%; hypercholesterolemia, 24%; AF, 16%; diabetes, 19%; prior MI, 11%; and prior TIA 12%. Hypercholesterolemia significantly increased over time (10.5%-31.7%, P<0.001); prior-to-stroke MI and TIA significantly reduced (MI 7.7%-2.7%, P<0.001; TIA, 16.3%-8.9%, P<0.001). Hypertension, AF, and diabetes did not change significantly over time.
Risk factor associations
The multivariate analyses are reported in Hypertension prevalence was similar in ischemic stroke and ICH, but significantly lower in SAH (aRR v ischemic stroke 0.63, 95% CI 0.52-0.75).
Hypercholesterolemia, diabetes, prior MI, and AF were significantly less prevalent in ICH and SAH than ischemic stroke.
Prescribing trends
Trends in prescribed medication are reported in table 1 and figure 2. 26% of patients had a single untreated risk factor, 13% had 2 or more. The proportions of those with risk factors prescribed appropriate treatment were: hypertension 62%; hypercholesterolemia 75%; MI (antiplatelets) 62%; AF 64% (anticoagulants 17%; antiplatelets 48%; [1% both]); TIA (antiplatelets) 58%. Prescribed treatment for hypercholesterolemia increased over time (70%-77%, P=0.004). Antiplatelet prescription for AF significantly increased (37%-51%, P<0.001); anticoagulant prescription increased, but was not significant (12%-23%, P=0.059). Antiplatelet prescription in MI and TIA significantly increased over time (MI, 48%-60%, P<0.001; TIA, 49%-61%, P=0.015). Antihypertensive prescription did not significantly change over time.
Associations with appropriate treatment
The multivariate analyses are reported in table 3. Anticoagulant prescription in AF for older patients was low, and least in those aged ≥85 (aRRs v <65s; 65-74: 0.41, 75-84: 0.77, ≥85: 0.19). Significantly more women with hypertension were treated than men; there were no significant differences for other risk factor treatments between sexes.
Significantly more black patients with hypertension were treated than white patients (aRR 1.17, 95% CI 1.10-1.15). There was no significant association between other risk factor treatments and ethnicity, or between deprivation and any risk factor treatment. ICH and SAH were associated with significantly higher anticoagulant prescription (aRR v ischemic stroke: ICH 3.14, 95% CI 2.21-4.04; SAH 4.64, 95% CI 2.40-5.72).
Discussion
This paper analyses trends in the prevalence and treatment of risk factors priorto-stroke over 15 years. Hypercholesterolemia increased significantly over time, and prior MI and TIA fell. Prescribing of antiplatelets and cholesterol-lowering treatments significantly increased over the study period. A minority with AF were prescribed anticoagulants; this did not significantly improve over time, and was least likely in older people. Overall, one third of first strokes occurred in people who were not prescribed treatment for a previously diagnosed risk factor.
Anticoagulants are effective for the prevention of AF-related stroke; a 2007 meta-analysis found anticoagulation was substantially more effective than aspirin. [17] A UK consensus statement published after the SLSR data were collected recommended that aspirin is no longer used for stroke prevention in AF. [18] Anticoagulant prescribing for AF remained low throughout the study period, and was lowest in older patients, among whom AF was most prevalent.
UK research found significantly lower primary prevention use among older people, despite advancing age being the most important risk factor for vascular disease. [19] The SLSR did not record contraindications to anticoagulants, though US research found low warfarin use even among those with no contraindications. [6] These results provide an example of delay in implementing evidence-based practice. [20] Guidelines recommending anticoagulation for AF were published in the early 1990s. [21] Barriers to anticoagulant use have been examined in qualitative research, and include perceived high rates of bleeding, particularly in the elderly, and clinicians' perceptions that patients would not agree to treatment. [22] However, an RCT in people aged over 75 found that warfarin was more effective than aspirin in preventing stroke, with no increase in hemorrhage. [23] The SLSR data suggest that there is room for improvement in the use of anticoagulation in AF.
Consistent with previous studies, [10] this study found that AF was substantially less prevalent in black than white stroke patients. This difference was not caused by underdiagnosis: a similar discrepancy was found on ECG on hospital admission. This difference may be explained by lower AF prevalence in black people in the general population, [24] and ethnic differences in the etiological role of AF in stroke. [25] RCTs of anticoagulation in AF were conducted overwhelmingly in white populations; only 6% of participants were non-white. [25] Additionally, tools for identifying AF patients at highest risk, CHADS2 and CHA2DS2-VASc, do not incorporate ethnicity and have not been validated in black populations. [26, 27] A US observational study found increased warfarin-related intracranial hemorrhage in black compared with white patients. [28] These data question whether the balance of benefit and harm with anticoagulation may vary among different ethnic groups. [28] Previous studies have found that ethnic minority populations have inadequate access to healthcare. [29] We found no difference in risk factor treatment between ethnic groups, except for hypertension, with significantly more black patients treated than white patients. Here, we did not assess risk factor control, but merely whether treatment was prescribed. UK observational studies have reported significantly worse control in black compared with white patients. [30, 31] There was a reduction in patients with untreated risk factors from 40% in 1995-98 to 17% in 1999-2002, followed by increases until 2010, although the overall trend was not significant. This change from 1995-98 to 1999-2002 was principally caused by a large increase in hypertension treatment from 52-74%.
This improvement was not sustained; rates reduced to 55% by 2007-10. The reason for these changes is unclear, but migration in the source population may have contributed. According to census data, from 1991-2001 the number of black African residents increased (7-15%) and the number of white fell (72-63%).
In the SLSR, deprivation was not associated with significant differences in risk factors or prescribed treatments, and was not responsible for ethnic differences in risk factors. This contrasts with US research, which reported that income differences explained much of the difference in risk factor prevalence between white and African American patients. [12] This discrepancy may reflect differences in healthcare for deprived populations between the UK and US; US research has found inadequate risk factor management was more likely in people without health insurance. [32] The reduction in prior MI among first-stroke patients is likely to reflect a reduction in MI in the general population; possible contributing factors include increasing use of primary prevention and a 2007 UK smoking ban in public places. [33] Risk factor prevalences are susceptible to changes in diagnostic cutoffs over time. UK hypertension guidelines have recommended similar cutoffs over the study period (>160/100mmHg, or >140/90 with other risk factors); [34, 35] diagnostic criteria for diabetes were lowered in 1999 from a fasting blood glucose ≥7.8mmol/l to ≥7.0mmol/l. [36] European guidelines on hypercholesterolemia were published in 1998, recommending a diagnostic cutoff of total cholesterol ≥5, or LDL cholesterol ≥3; [37] subsequent revisions recommend treatment based on overall cardiovascular risk. [38] The large increase in hypercholesterolemia is likely to be explained by increased detection.
Strengths and limitations
This study was population based, with multiple notification sources including hospitalised and community stroke patients. Risk factor diagnoses were collected from patient medical records. Though bias may occur through changes in documentation practice over the time period, this was mitigated by using both hospital and GP records. This study did not collect individual blood pressure or serum cholesterol values; therefore, the results represent rates of detected risk factors and omit those who were unaware.
It is not possible to draw conclusions from this study about primary prevention uptake in the general population. The stroke population is more likely to contain people with multiple and inadequately treated risk factors. Indeed, the number of people with a first stroke reduced over time, which could be consistent with improvements in prevention. This study does provide evidence, however, that a substantial number of stroke patients were not prescribed optimal treatment for previously diagnosed risk factors.
Conclusions
There have been significant improvements in the use of appropriate antiplatelet and cholesterol-lowering treatments; however, almost one third of strokes occurred in patients with diagnosed but untreated risk factors. Anticoagulant prescription in AF remained low throughout the study period, and was lowest in older people. These results highlight a need for continued research into interventions to improve uptake of primary prevention. Table 3 -Association of demographics and stroke subtype with prescribed preventative medication: RRs with 95% CI; columns show results from a logistic regression model with the risk factor as the dependent variable; *=reference category
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